GlassScriptPhysician profile
Scott D Parker
NPI 1992716120
$10,567.41
in general payments reported to CMS, 2019-2025
39 companies · $2,293 in 2025
The $2,293 reported for 2025 was more than what 86% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $800 · 2021: $1,350 · 2022: $1,780 · 2023: $1,671 · 2024: $1,871 · 2025: $2,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,514 · Education: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,514.47 |
| Education | $319.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,944.67 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Insmed, INC. | $1,245.81 | 2019-2025 | Arikayce, Brinsupri |
| Melinta Therapeutics, LLC | $982.22 | 2019-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Merck Sharp & Dohme LLC | $768.37 | 2019-2025 | Pifeltro, Zerbaxa, Dificid |
| Abbvie INC. | $764.53 | 2021-2025 | |
| Astellas Pharma US INC | $747.78 | 2019-2025 | Cresemba |
| Gilead Sciences, INC. | $663.10 | 2019-2025 | |
| Csl Behring | $513.06 | 2024-2025 | Hizentra |
| Cumberland Pharmaceuticals, INC. | $403.74 | 2020-2025 | Vibativ, Caldolor |
| Smith+Nephew, INC. | $373.11 | 2022-2025 | Stravix, Collagenase Santyl, Grafix Pl |
| La Jolla Pharmaceutical Company | $280.37 | 2020-2024 | Xerava, Xacduro |
| Theratechnologies INC. | $197.14 | 2019-2025 | Egrifta, Trogarzo |
| Janssen Biotech, INC. | $188.18 | 2019-2023 | Symtuza |
| Janssen Products, LP | $184.95 | 2019-2022 | |
| Mimedx Group, INC. | $165.16 | 2024-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $152.30 | 2023-2025 | Rebyota |
| Mayne Pharma Commercial LLC | $103.81 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $93.22 | 2020-2023 | Nuzyra |
| Aimmune Therapeutics, INC. | $90.43 | 2023-2025 | Vowst |
| Pfizer INC. | $87.87 | 2023-2025 | |
| Aroa Biosurgery Incorporated | $83.86 | 2023-2024 | |
| Tetraphase Pharmaceuticals, INC. | $62.99 | 2019-2020 | |
| Organogenesis INC. | $58.97 | 2023-2025 | Puraply, Puraply Wound Matrix |
| Takeda Pharmaceuticals U.S.A., INC. | $58.82 | 2022 | |
| Convatec INC. | $41.82 | 2025 | |
| Allergan, INC. | $41.06 | 2019-2020 | |
| Grifols USA, LLC | $35.59 | 2023-2025 | Xembify |
| Triad Life Sciences INC. | $27.87 | 2022 | |
| Pharming Healthcare, INC. | $27.18 | 2023 | Ruconest |
| Polynovo North America LLC | $26.58 | 2022-2023 | |
| Solventum Corporation | $26.01 | 2024 | 3m Cavilon, Activ.A.C., Kerramax Care |
| Kerecis Limited | $20.12 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Hydrofera LLC | $18.17 | 2022 | |
| Urgo Medical North America, LLC | $17.73 | 2025 | Urgoclean Ag |
| Tactile Systems Technology INC | $16.08 | 2025 | Flexitouch Plus, Nimbl |
| Eisai INC. | $15.76 | 2021 | |
| Nabriva Therapeutics, Plc | $13.98 | 2020 | |
| Shionogi INC | $13.77 | 2023 | Fetroja |
| Bio Products Laboratory USA, INC. | $11.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.